<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362659">
  <stage>Registered</stage>
  <submitdate>21/06/2012</submitdate>
  <approvaldate>22/06/2012</approvaldate>
  <actrnumber>ACTRN12612000669897</actrnumber>
  <trial_identification>
    <studytitle>A study of the effect of preoperative chemoradiotherapy on sexual dysfunction in men with locally advanced rectal cancer</studytitle>
    <scientifictitle>A single arm prospective study of the effect of preoperative chemoradiotherapy on sexual dysfunction in men with locally advanced rectal cancer</scientifictitle>
    <utrn>U1111-1132-0132</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rectal Cancer</healthcondition>
    <healthcondition>Male Sexual Dysfunction</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Observational Study of male sexual dysfunction.  Duration of observation 18 months.  Assessments will be made at baseline (before radiotherapy) and at 3, 6,9, 12 and 18 months following radiotherapy.</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of male sexual dysfunction at 6months post-treatment, as defined by an IIEF (International Index of Erectile Function</outcome>
      <timepoint>At 6 months following radiotherapy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1.the rate of Leydig cell dysfunction at 6 months post-radiotherapy based on evaluation of serum testosterone/FSH and LH levels.</outcome>
      <timepoint>Assessed at 6 months post-radiotherapy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. the median radiation dose to the testicles during chemoradiotherapy for rectal cancer based on TLD/OSLD measurements and radiotherapy planning software dose calculations.</outcome>
      <timepoint>Assessed during radiotherapy treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Penile bulb dose-volume constraints. Based on review of the doses received to the penile bulb during radiotherapy (derived from the radiotherapy treatment plan)</outcome>
      <timepoint>Assessed at 18 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Age &gt;18years
2.Male
3.Histologically confirmed rectal adenocarcinoma
4. Stage T3-4N0 or N1 disease 
5. Requires pre-operative radiotherapy or chemoradiotherapy followed by TME resection
6. Provide informed consent 
7. Able to complete sexual function and quality of life questionnaire</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Prior pelvic radiotherapy
2. History of impotence
3. Inflammatory bowel disease
4. Prior pelvic surgery
5. Receiving hormonal treatment for prostate cancer
6. Patients taking testosterone supplements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/08/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Catherine Bettington</primarysponsorname>
    <primarysponsoraddress>Cancer Care Services
Royal Brisbane and Women's Hospital
Butterfield St
Herston 
Queensland 4029</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Michelle Grogan</sponsorname>
      <sponsoraddress>Cancer Care Services
Royal Brisbane and Women's Hospital
Butterfield St
Herston 
Queensland 4029</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Matthew Burge</othercollaboratorname>
      <othercollaboratoraddress>Cancer Care Services
Royal Brisbane and Women's Hospital
Butterfield St
Herston 
Queensland 4029</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to assess rate of sexual dysfunction in men following treatment with radiotherapy and surgery for rectal cancer.  It aims to identify potential causes of sexual dysfunction in this group of patients, including assessing testicular hormone function following this treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital Human Ethics Review Committee</ethicname>
      <ethicaddress>Butterfield St
Herston QLD 
4029</ethicaddress>
      <ethicapprovaldate>13/06/2012</ethicapprovaldate>
      <hrec>HREC/12/QRBW/129</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Catherine Bettington</name>
      <address>Cancer Care Services
Royal Brisbane and Women's Hospital
Butterfield St
Herston
Queensland 4029</address>
      <phone>+61 7 3636 8111</phone>
      <fax />
      <email>Catherine_Bettington@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Jacqui Keller</name>
      <address>Clinical Trials Office
Cancer Care Services
Royal Brisbane and Women's Hospital
Butterfield St
Herston 
Queensland 4029</address>
      <phone>+61 7 36367925</phone>
      <fax />
      <email>Jacqui_Keller@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Catherine Bettington</name>
      <address>Cancer Care Services
Royal Brisbane and Women's Hospital
Butterfield St
Herston
Queensland 4029</address>
      <phone>+61 7 3636 8111</phone>
      <fax />
      <email>Catherine_Bettington@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>